Vera Therapeutics (VERA) Stock Price, News & Analysis

+0.39 (+1.00%)
(As of 04/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.22 million shs
Average Volume
1.16 million shs
Market Capitalization
$2.15 billion
P/E Ratio
Dividend Yield
Price Target

Vera Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
18.3% Downside
$32.29 Price Target
Short Interest
16.12% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Selling Shares
$21.53 M Sold Last Quarter
Proj. Earnings Growth
From ($2.18) to ($2.45) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.57 out of 5 stars

Medical Sector

856th out of 909 stocks

Pharmaceutical Preparations Industry

401st out of 425 stocks

VERA stock logo

About Vera Therapeutics Stock (NASDAQ:VERA)

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

VERA Stock Price History

VERA Stock News Headlines

Elon Musk’s Controversial New Project: “Apollo”
Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...
Elon Musk’s Controversial New Project: “Apollo”
Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...
Vera Therapeutics: Waiting For A Pullback
Vera Therapeutics: Q4 Earnings Insights
VERA Mar 2024 17.500 call
VERA Apr 2024 40.000 call
VERA Apr 2024 50.000 put
See More Headlines
Receive VERA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
8 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$1.94 per share


Free Float
Market Cap
$2.15 billion
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Sean P. Grant M.B.A. (Age 39)
    Chief Financial Officer
    Comp: $585.5k
  • Mr. Joseph R. Young M.B.A. (Age 51)
    Senior VP of Finance & Chief Accounting Officer
  • Mr. Julien E. Capers J.D.
    VP & Head of Legal
  • Ms. Kelly Rauber
    VP & Head of Human Resources
  • Mr. Tom Doan (Age 52)
    Senior Vice President of Development Operations
  • Ms. Lauren Frenz (Age 39)
    Chief Business Officer
  • Dr. Neeraj Pakala M.B.A.
    Ph.D., Senior VP and Head of Product Development & Manufacturing
  • Dr. Kerry Cooper M.D.
    Senior Vice President of Medical Affairs
  • Dr. Robert M. Brenner M.D. (Age 56)
    Chief Medical Officer
  • Mr. William D. Turner (Age 57)
    Chief Development Officer

VERA Stock Analysis - Frequently Asked Questions

Should I buy or sell Vera Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vera Therapeutics in the last year. There are currently 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VERA shares.
View VERA analyst ratings
or view top-rated stocks.

What is Vera Therapeutics' stock price target for 2024?

8 brokerages have issued 1-year target prices for Vera Therapeutics' shares. Their VERA share price targets range from $22.00 to $56.00. On average, they expect the company's share price to reach $32.29 in the next year. This suggests that the stock has a possible downside of 18.3%.
View analysts price targets for VERA
or view top-rated stocks among Wall Street analysts.

How have VERA shares performed in 2024?

Vera Therapeutics' stock was trading at $15.38 at the start of the year. Since then, VERA stock has increased by 157.0% and is now trading at $39.52.
View the best growth stocks for 2024 here

When is Vera Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VERA earnings forecast

How were Vera Therapeutics' earnings last quarter?

Vera Therapeutics, Inc. (NASDAQ:VERA) issued its earnings results on Wednesday, March, 20th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by $0.05.

When did Vera Therapeutics IPO?

Vera Therapeutics (VERA) raised $66 million in an initial public offering on Friday, May 14th 2021. The company issued 4,400,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI served as the underwriters for the IPO.

How do I buy shares of Vera Therapeutics?

Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VERA) was last updated on 4/24/2024 by Staff

From Our Partners